Literature DB >> 31425493

Excretion of Antipsychotics Into the Amniotic Fluid, Umbilical Cord Blood, and Breast Milk: A Systematic Critical Review and Combined Analysis.

Georgios Schoretsanitis1, Andreas A Westin2, Kristina M Deligiannidis1,3,4, Olav Spigset2,5, Michael Paulzen6,7.   

Abstract

BACKGROUND: Antipsychotics are being increasingly prescribed during pregnancy and in the postpartum period. However, knowledge regarding the ability of antipsychotics to enter the fetal, newborn, and infant circulation presents inconsistencies. Evidence for penetration ratios in an array of matrices will contribute to further studies examining the mechanistic pathway from antipsychotic use to adverse events.
METHODS: A systematic literature search of PubMed and EMBASE was performed to identify studies assessing the concentrations of antipsychotics in maternal blood (serum or plasma), amniotic fluid, umbilical cord blood, and/or breast milk. The penetration ratios were estimated by dividing the antipsychotic concentrations in the target matrix (ie, amniotic fluid, umbilical cord blood or breast milk) by the maternal concentration. Data are provided in means with ranges or SD depending on data availability.
RESULTS: Forty-nine eligible studies were identified. For amniotic fluid, the penetration ratios were estimated for quetiapine, clozapine, and flupentixol, with quetiapine displaying the highest ratio (mean 0.59, range 0.09-1.70 versus 0.56, range 0.31-0.82 for clozapine and 0.24, range 0.23-0.24 for flupentixol). For umbilical cord blood, olanzapine had the highest ratio (mean 0.71 ± 0.42) followed by haloperidol (mean 0.66 ± 0.40) and paliperidone (mean 0.53, range 0.50-0.58). In case of breast milk, the highest ratio was observed for amisulpride (mean 14.42, range 11.86-19.50) followed by clozapine (mean 3.19, range 2.79-4.32) and haloperidol (mean 3.11, range 0.59-6.67).
CONCLUSIONS: The ability of antipsychotics to enter the fetal, newborn, and infant circulation varies considerably among antipsychotics. Given sampling constraints of other matrices, measuring antipsychotic concentrations in maternal blood may represent the least expensive, most readily available, and reliable estimate of fetal/infant exposure.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31425493     DOI: 10.1097/FTD.0000000000000692

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis.

Authors:  Georgios Schoretsanitis; Olav Spigset; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Andreas A Westin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-04-10       Impact factor: 4.481

2.  Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis.

Authors:  Georgios Schoretsanitis; Andreas A Westin; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Olav Spigset
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-01-02       Impact factor: 5.067

Review 3.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11

Review 4.  Antipsychotic medication for women with schizophrenia spectrum disorders.

Authors:  Bodyl A Brand; Yudith R A Haveman; Franciska de Beer; Janna N de Boer; Paola Dazzan; Iris E C Sommer
Journal:  Psychol Med       Date:  2021-11-12       Impact factor: 10.592

5.  Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose.

Authors:  Jeffrey Wald; Anja Henningsson; Eva Hanze; Ethan Hoffmann; Haihong Li; Helen Colquhoun; Kristina M Deligiannidis
Journal:  Clin Pharmacokinet       Date:  2022-07-23       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.